- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoint Inhibitors in the Treatment of HCC
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-01-09
DOI
10.3389/fonc.2020.601240
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2020) Peter R. Galle et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in advanced hepatocellular cancer (HCC).
- (2020) Rohit Gosain et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040.
- (2020) Aiwu Ruth He et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study
- (2020) Luca Faloppi et al. Targeted Oncology
- Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: results of the multicenter prospective INNOVATE study
- (2020) Andrea Casadei Gardini et al. CLINICAL CANCER RESEARCH
- A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.
- (2020) Wai Meng David Tai et al. JOURNAL OF CLINICAL ONCOLOGY
- Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib
- (2020) Andrea Casadei-Gardini et al. MEDICINE
- The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib
- (2020) Francesco Caputo et al. PLoS One
- LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma
- (2020) B. Sangro et al. ANNALS OF ONCOLOGY
- O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma
- (2020) R. Kelley et al. ANNALS OF ONCOLOGY
- Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
- (2019) Bridget Keenan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
- (2019) Kristen Renee Spencer et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
- (2019) Serena De Matteis et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC) following progression on systemic treatment(s).
- (2019) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
- (2019) Josep M Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
- (2019) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
- (2019) Andrea Casadei Gardini et al. OncoTargets and Therapy
- Stereotactic body radiation therapy in patients with hepatocellular carcinoma: A mini-review
- (2019) Sabine Gerum et al. World Journal of Gastrointestinal Oncology
- Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications
- (2019) Elisabetta Cariani et al. LIVER INTERNATIONAL
- New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
- (2019) Mossenta et al. Cancers
- ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
- (2019) Giorgia Marisi et al. Cancers
- FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
- (2019) Aroosha Raja et al. Cells
- LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
- (2019) K Fizazi et al. ANNALS OF ONCOLOGY
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- LBA1Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
- (2019) R Camidge et al. ANNALS OF ONCOLOGY
- 91O A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC)
- (2019) M Hidalgo et al. ANNALS OF ONCOLOGY
- Emerging agents and regimens for hepatocellular carcinoma
- (2019) Xiao-Dong Zhu et al. Journal of Hematology & Oncology
- TGF-β1 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression
- (2018) Jiawei Huang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma
- (2018) Matteo Canale et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
- (2018) Marco B. Schaaf et al. Cell Death & Disease
- Immunotherapy of Hepatocellular Carcinoma
- (2018) Bernd Heinrich et al. Oncology Research and Treatment
- Characterization of Hepatocellular Carcinoma Patients with FGF19 Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort Study
- (2018) Hyo Jeong Kang et al. Liver Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2018) Masafumi Ikeda et al. JOURNAL OF CLINICAL ONCOLOGY
- REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
- (2018) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol
- (2018) Andrea Casadei Gardini et al. TUMORI
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
- (2018) Giorgia Marisi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- 615ORandomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)
- (2018) D Sakai et al. ANNALS OF ONCOLOGY
- The Role of Angiogenesis in Hepatocellular Carcinoma
- (2018) Michael A. Morse et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
- (2018) Yu-Yang Lin et al. SEMINARS IN LIVER DISEASE
- Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
- (2017) Andrea Casadei Gardini et al. EUROPEAN JOURNAL OF CANCER
- Transforming Growth Factor-β Drives the Transendothelial Migration of Hepatocellular Carcinoma Cells
- (2017) Petra Koudelkova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
- (2017) Jianhua Liu et al. ONCOLOGY REPORTS
- Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model
- (2017) Xiulan Lai et al. PLoS One
- Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma
- (2017) Giovan Giuseppe Di Costanzo et al. Targeted Oncology
- Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma
- (2017) Xiaomeng Dai et al. Translational Oncology
- Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report
- (2017) Lixia Gao et al. CELLULAR ONCOLOGY
- Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
- (2017) Andrea Casadei Gardini et al. Oncotarget
- Immunotherapeutic approaches for hepatocellular carcinoma
- (2017) Vito Longo et al. Oncotarget
- Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
- (2017) Jonathan M. Yingling et al. Oncotarget
- Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply
- (2017) Ken Liu et al. Clinical and Translational Gastroenterology
- Immuno-thermal ablations – boosting the anticancer immune response
- (2017) Ryan Slovak et al. Journal for ImmunoTherapy of Cancer
- High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
- (2016) Fabian Finkelmeier et al. EUROPEAN JOURNAL OF CANCER
- Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features
- (2016) Julien Calderaro et al. HEPATOLOGY
- Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
- (2016) Xian-Shu Gao et al. OncoTargets and Therapy
- eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
- (2016) Luca Faloppi et al. Biomed Research International
- Novel TGF-β inhibitors ready for prime time in onco-immunology
- (2016) Armand de Gramont et al. OncoImmunology
- A Meta-Analysis of Adjuvant Therapy after Potentially Curative Treatment for Hepatocellular Carcinoma
- (2016) Jun Wang et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
- (2015) James J. Harding et al. CANCER
- Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
- (2015) Jiang Chen et al. CANCER LETTERS
- Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib
- (2015) Andrea Casadei Gardini et al. EXPERT OPINION ON PHARMACOTHERAPY
- Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
- (2015) Antonio Gnoni et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Immunogenic cell death
- (2015) Abhishek D. Garg et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- Targeting the TGFβ pathway for cancer therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
- (2014) Luca Faloppi et al. BMC CANCER
- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
- (2014) Mario Scartozzi et al. INTERNATIONAL JOURNAL OF CANCER
- The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment
- (2014) Marco D'Anzeo et al. MOLECULES
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Control of the Immune Response by Pro-Angiogenic Factors
- (2014) Thibault Voron et al. Frontiers in Oncology
- Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma
- (2013) Jiyeon Hyeon et al. DIGESTIVE DISEASES AND SCIENCES
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- A systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm
- (2013) Ai Shen et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
- (2012) Mario Scartozzi et al. PLoS One
- Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
- (2011) Eric T. Sawey et al. CANCER CELL
- Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
- (2011) Mario Scartozzi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria
- (2010) Jiwei Huang et al. ANNALS OF SURGERY
- Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options
- (2010) Luca Faloppi et al. CANCER TREATMENT REVIEWS
- PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
- (2010) Feng Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Intra-arterial brachytherapy of hepatic malignancies: watch the flow
- (2010) Bruno Morgan et al. Nature Reviews Clinical Oncology
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- VEGFR2 is selectively expressed by FOXP3high CD4+ Treg
- (2009) Hiroyuki Suzuki et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma
- (2009) Adam J. Gehring et al. GASTROENTEROLOGY
- Vascular Changes in Hepatocellular Carcinoma
- (2008) Zhen Fan Yang et al. Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulatory T Cells: Mechanisms of Differentiation and Function
- (2007) Steven Z. Josefowicz et al. Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now